Investors
CEO Message
We sincerely appreciate your continued support.
Our company's core development pillar is "Aptamer Drug Discovery," which utilizes the "flexible shaping power" of single-stranded nucleic acids (particularly RNA).
Regarding our lead development candidate, umedaptanib pegol (anti-FGF2 aptamer), clinical trials (Phase 2) are progressing for exudative age-related macular degeneration and achondroplasia.
For exudative age-related macular degeneration, we confirmed proof of concept (POC) in a Phase 2 clinical trial conducted in the United States.
For achondroplasia, the Phase 2 clinical trial conducted in Japan has been completed, and POC has also been confirmed for this indication. Currently, we are advancing pre-submission consultations with the Pharmaceuticals and Medical Devices Agency (PMDA) to initiate Phase 3 clinical trials for regulatory submission. Last year, this program received Orphan Drug Designation (ODD) from the Ministry of Health, Labour and Welfare, enabling us to anticipate various preferential measures for future development.
The fact that our umedaptanib pegol has demonstrated clinical efficacy in these two diseases is not only excellent news for our company but is also expected to provide significant momentum for the development of aptamer therapeutics, which has been sluggish globally to date.
Furthermore, in basic research, we are seeing results from new technological developments, such as AI-driven aptamer creation technology and aptamer delivery technology. By leveraging these, we will advance implementation toward commercialization and strive diligently to deliver our drugs to patients who need them.
We extend our deepest gratitude to the many individuals who have supported us thus far. We will redouble our efforts to meet the expectations of our shareholders.
Yoshikazu Nakamura PhD. President and CEO
January 2026
Corporate Philosophy
Regardless of the progress made in science and technology, many medical needs remain unmet for cancer, immune disorders, and other incurable diseases. Our objective is to discover innovative aptamer medicines for difficult to treat and incurable diseases in collaboration with other pharmaceutical companies. We plan to launch aptamer medicines as soon as possible to contribute to the health of people.
Fundamental policies for realizing the corporate philosophy
- As a corporation involved in the research and development of pharmaceutical drugs for human life and health, we conduct research based on cutting-edge science and technology with an emphasis on high ethical standards.
- To maximize corporate value and fulfill our social responsibility, we work to strengthen our commitment to the Structure of Corporate Governance and maintain compliance and the appropriate corporate execution of business.
- As a listed corporation, we observe the Standards of Corporate Action developed by the Tokyo Stock Exchange, enhance the disclosure of corporate information, secure the transparency of corporate management, and ensure accountability. Furthermore, we maintain and develop good relationships with shareholders, customers, the local community and other stakeholders.